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Abstract
Objectives: Ambulance officers administering methoxyflurane as an inhalational analgesic may be exposed to trace vapor. Fluoride is a methoxyflu-
rane metabolite, and has been associated with acute renal failure in anesthesia patients and skeletal fluorosis with chronic elevated serum levels from 
other sources. However, there has been no direct measurement of serum fluoride in occupationally exposed ambulance officers. Thus, this study 
directly measures serum fluoride over a prolonged period in order to determine renal toxic and skeletal fluorosis risk to ambulance officers who are 
administering methoxyflurane. Material and Methods: Serum inorganic fluoride concentrations were measured in a prospective observational study 
of 12 emergency medical technicians (EMTs). The study took 7 serum fluoride measurements over 24 months. A meta-analysis of healthy adult serum 
fluoride ranges was also conducted. Results: The typical healthy adult serum fluoride range was determined to be 0.21–2.11 μmol/l (p < 0.001). The 
EMTs’ baseline median (IQR) serum fluoride concentrations were 0.4 μmol/l (0.2; 1.0) with maximum 1.6 μmol/l. The EMTs’ overall median serum 
fluoride was 0.4 μmol/l [0.2; 1.3] with maximum 4.0 μmol/l, usually within healthy reference ranges. All results were ≤10% of the suggested single-dose 
renal toxic threshold. One result was above a threshold for skeletal fluorosis. The highest measured serum fluoride was 24% of the lowest level associ-
ated with radiologic evidence of fluorosis. There was no evidence overall of increasing serum fluoride levels. Conclusions: There was no evidence that 
EMTs’ exposure to methoxyflurane resulted in sustained increased serum fluoride. These results imply EMTs’ occupational safety from acute renal 
toxicity when activated carbon filtration is used on patient exhalation. However, 1 serum fluoride result above a skeletal fluorosis threshold suggests 
that the risk of mild skeletal fluorosis cannot be excluded. Int J Occup Med Environ Health. 2021;34(6)
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quired to confirm an absence of compartment saturation 
with delayed serum fluoride increase.
A further health concern, i.e., skeletal fluorosis, is caused 
by the accumulation of fluoride in bones over a prolonged 
period leading to stiffness, pain, connective tissue calci-
fication, osteosclerosis, bone deformities, and increased 
fracture risk [16,17]. Skeletal fluorosis might be a poten-
tial long-term occupational hazard due to fluoride metab-
olite deposition from methoxyflurane [14,18]. Therefore, 
direct serum fluoride measurement is also important to 
investigate skeletal fluorosis risk. A threshold for serum 
fluoride levels associated with the onset of skeletal fluoro-
sis is not immediately apparent in the literature [19–22]. 
Therefore, meta-analysis of the serum fluoride of the gen-
eral public is also required to identify a healthy serum flu-
oride range not associated with skeletal fluorosis, against 
which individuals exposed to methoxyflurane might be 
compared.
This research hypothesized that emergency medical tech-
nicians (EMTs) would exhibit increasing serum fluoride 
concentrations after introduction of methoxyflurane. 
The absence of reported adverse effects due to occupa-
tional exposure was noted [23]. However, the accumula-
tion of fluoride following repeated occupational exposure 
to methoxyflurane vapor has not been previously stud-
ied, and identifying whether such accumulation occurs is 
a necessary first step to quantifying risk and optimizing 
safety. Thus, this study directly measured serum fluoride 
over a prolonged period in order to determine renal toxic 
and skeletal fluorosis risk to ambulance officers who are 
administering methoxyflurane.
MATERIAL AND METHODS
The study was approved by the University of Canterbury 
Human Ethics Committee with ref. No. HEC 2017/23/LR, 
and by the ambulance service Research Committee. The 
study was registered with the Australian New Zealand Clin-
ical Trials Registry with ID No. ACTRN12617001334392. 
INTRODUCTION
Methoxyflurane is a volatile halogenated ether [1] recom-
mended for use as an inhaled analgesic for pre-hospital 
and other pain relief [2,3]. Methoxyflurane undergoes he-
patic metabolism [1], producing fluoride and other prod-
ucts. Approximately two-thirds of these products are ex-
creted in urine over subsequent days [4]. An association 
exists between increased fluoride metabolite concentra-
tion in blood and increased nephrotoxicity [5–8]. A high-
dose anesthetic use of methoxyflurane has thus been as-
sociated with renal failure [9,10].
In contrast, low-dose analgesia administered to patients 
and the environmental concentrations to which health-
care staff are exposed are believed to be well below 
a level that might cause renal toxicity [6]. Calculations of 
risk have relied on extrapolation over several orders of 
magnitude and, therefore, require verification [7,11]. In-
ternational limit values (ILVs) have been set at 2 ppm for 
8-hour exposure [12]. In a clinical setting with modern 
use, cohort mean 8-hour exposure to methoxyflurane 
was below the ILVs. However, the highest 8-hour expo-
sure in that setting was 2.88 ppm, which exceeds those 
limits [13]. Direct measurement of fluoride levels in 
workers consistently exposed to methoxyflurane has not 
been undertaken and is, therefore, needed to confirm 
renal safety.
Another reason for direct measurement is to ascertain 
temporal effects such as fluoride accumulation due to re-
peated exposure. Approximately one-third of absorbed 
methoxyflurane and metabolites remain in the body 9 days 
following exposure [4]. Rodent skeletal fluoride content 
was found to increase following methoxyflurane expo-
sure [14,15], suggesting that compartmental storage and 
saturation might result in a delayed increase in serum 
fluoride. This outcome suggests, for frequently exposed 
individuals, the possibility of serum fluoride reaching 
renal toxic levels with some delay. Therefore, direct meas-
ure ment of serum fluoride over a prolonged period is re-
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for the collection, analysis, and publication of serum flu-
oride results.
The inclusion criteria were as follows:
 – EMTs’ practice level;
 – employment in full-time patient contact duties by 
the ambulance service;
 – age ≥18 years.
The reason why EMTs were recruited was that they can 
administer oral or inhaled analgesia agents, including me-
thoxyflurane, but not intravenous agents [25]. Hence, it 
was assumed that EMTs would be more likely than other 
qualified staff to utilize methoxyflurane, and thus to be 
most exposed to methoxyflurane vapor. There were no ex-
clusion criteria. The authors did not seek or obtain ethical 
approval to collect data on the participants’ characteristics 
such as age, weight, or sex.
Blood serum measurements were taken in months 0, 1, 4, 8, 
12, 18, and 24 following the introduction of methoxyflurane. 
The participants were e-mailed reminders at the start and 
mid-point of each of the 7 study months to provide a blood 
sample at a day and time convenient to them. Blood sam-
pling was performed by a trained phlebotomist at a clinic 
convenient to each participant. Samples were separated lo-
cally and serum was sent to Canterbury Health Laborato-
ries, Christchurch, New Zealand for analysis. Serum fluoride 
concentration was measured by a Thermo Scientific™ Orion 
Star™ A214 pH/ISE Benchtop Meter with a Thermo Scien-
tific™ fluoride ion specific electrode. Equipment was cali-
brated by the laboratory using suitable sodium fluoride stan-
dards in accordance with the manufacturer’s instructions. 
Uncertainty of measurement was ±0.48 μmol/l at 1 μmol/l, 
and ±2.11 μmol/l at 27 μmol/l. The lower limit of quantifica-
tion was 0.2 μmol/l. Canterbury Health Laboratories is an 
entity accredited by International Accreditation New Zea-
land (IANZ) in all disciplines and for all medical testing pro-
cedures it performs, and is ISO 15189 accredited.
Exposure frequency data were not recorded due to an 
inability to directly observe the cohort, concern about 
Written informed consent was obtained from all partici-
pants prior to any blood measurement.
Meta-analysis of published serum fluoride levels associat-
ed with healthy individuals was performed by the following 
process. First, the healthy reference range for serum fluo-
ride was determined by searching PubMed for literature 
reporting serum fluoride in healthy adults. The inclusion 
criteria were as follows: any study reporting serum fluo-
ride levels for a group consisting of healthy persons with 
an absence of reported skeletal fluorosis or altered renal 
function, regardless of their occupational or environmen-
tal exposure to fluoride or any substance believed to alter 
fluoride levels. Only English language studies were con-
sidered. The analysis was performed using R 3.6.1. Subse-
quently, the meta-analysis of search results was conducted 
by the generic inverse variance method with a random-
effects model [24].
A New Zealand metropolitan ambulance service intro-
duced methoxyflurane, administered via the Penthrox® 
inhaler with an activated carbon filter (Medical Develop-
ments International, Australia), as an analgesic option on 
June 1, 2017. Ambulance officers administered 3 or 6 ml to 
patients, as needed for analgesia [25]. The Penthrox® in-
haler contains a carbon filter which adsorbs vapor exhaled 
by the patient, limiting vapor from entering the workspace 
of the ambulance officer. However, uncertain patient com-
pliance with exhaling through the filter implied that staff 
would be exposed to some methoxyflurane vapor during 
administration [6].
A prospective observational cohort study was undertak-
en. At first, EMTs were recruited by general requests for 
participation sent via the ambulance service’s internal 
e-mail system, and respondents were provided further 
information and gave their written consent for participa-
tion, until the goal of 12 participants was achieved. This 
sample size was selected to provide 95% power to detect 
a 1 μmol/l difference between test results with p < 0.01, 
allowing for 30% attrition [26]. Consent was only given 
O R I G I N A L  P A P E R       S.J. ALLISON ET AL.
IJOMEH 2021;34(6)4
RESULTS
Identification of a healthy serum fluoride range
Overall, 8 studies reporting serum fluoride ranges in 
healthy adults were identified [19–21,27–31]. Insufficient 
statistical measures were provided in 1 study, preventing 
its inclusion in the meta-analysis [21]. One other study re-
ported ranges for men and women separately [28]. There-
fore, these ranges were input as separate samples for 
meta-analysis. None of the studies included New Zealand 
subjects. Meta-analysis, as shown in Figure 1, determined 
mean (95% CI) serum fluoride in healthy individuals to be 
1.16 μmol/l (0.21–2.11) with p < 0.001, indicating statisti-
cally significant homogeneity supporting this determina-
tion of a normal range.
Participants’ serum fluoride results
The target of recruiting 12 EMTs was achieved by June 15, 
2017. One participant withdrew late during the study and 
ethical constraints prohibit presentation or discussion of that 
person’s data. Some participants failed to undertake ≥1 tests. 
the reliability of the participants’ self-reporting, and ethi-
cal and time constraints in setting up the study.
Two-sample, 2-sided Wilcoxon signed-rank tests were per-
formed, comparing the serum fluoride results from each 
study month against the results from month 0, removing 
from each test any participants who had not provided 
a blood sample in both the specific month and month 0 to 
ensure pairing. Two-sample 2-sided Kolmogorov-Smirnov 
tests were performed, comparing all serum fluoride results 
for each participant with a constant serum fluoride value 
equal to that participant’s first test result. Statistical sig-
nificance for all tests was defined as p < 0.05. The Kol-
mogorov-Smirnov test was selected after all serum fluo-
ride test results had been received. Thus, results of that 
analysis should be regarded as hypothesis-generating.
The serum fluoride levels associated with skeletal fluoro-
sis were determined by searching PubMed for literature 
reporting this association. Engauge v. 10.10 software was 
used to determine the value of serum fluoride and bone 
mineral density data points in figures.
Taves (1966)
Husdan et al. (1976) – men
Husdan et al. (1976) – women
Torra et al. (1998)
Yildiz et al. (2003)
Rathee et al. (2004)
Susheela et al. (2013)




















































Heterogeneity: I2 = 94%, τ2 = 0.1975, p < 0.001.
The 95% CI was determined by the generic inverse variance method with a random-effects model, and is shown as the “prediction interval” (p < 0.001).
Figure 1. Forest plot of serum fluoride (SF) ranges of healthy individuals
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The resulting data set includes initial (baseline) values for 
9 participants and longitudinal results for 10 participants, 
as shown in Table 1. Some results were below the lower 
limit of quantification. The analysis (Tables 1 and 2, Fig-
ures 2 and 3) and discussion of the results assume those 
results to be equal to the lower limit of quantification: 
0.2 μmol/l. To determine whether this assumption intro-
duced error, an analysis was also performed with these 
values equal to 0.0, which did not elicit any new statistical 
significance in any results.
Longitudinal results for the participants are displayed in 
Figure 2, and summary statistics for each month are shown 
in Table 1 and Figure 3. The overall median (first quartile, 
third quartile) of serum fluoride was 0.4 μmol/l (first and 
third quartiles: 0.2, 1.3) with max 4.0 μmol/l. The p-values 
determined by Wilcoxon signed-rank tests for the differ-
ence between month 0 and each subsequent month are 
shown in Table 1, and support a conclusion that there is no 
statistically significant change in serum fluoride over time.
The results of Kolmogorov-Smirnov tests for 10 partici-
pants are shown in Table 2. This compares each partici-
One participant undertook only the initial blood test but did 
not withdraw formally from the study, and 6 participants pro-
vided blood samples for every requested study month.
Table 2. Results of Kolmogorov-Smirnov tests for each 
participant’s serum fluoride results against a constant serum 
fluoride value equal to that participant’s initial test result, 
following the introduction of methoxyflurane into clinical 




































































Figure 2. Serum fluoride results for participants 1–10, June 
2017–June 2019, New Zealand

















First and third quartiles
Vertical lines extend from the smallest observation greater than or 
equal to the first quartile minus 1.5 times the interquartile range,  
to the largest observation less than or equal to the third quartile 
plus 1.5 times the interquartile range; dots indicate outlier 
serum fluoride results not included within the vertical line range.
Figure 3. Box plots for serum fluoride in each test month, 
June 2017–June 2019, New Zealand
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ysis is important as it provides a comparison and evalu-
ation of the study of serum fluoride in ambulance staff 
exposed to a substance known to alter serum fluoride.
Serum fluoride concentration in month 0 established 
a participant’s baseline serum fluoride of 0.2–1.6 μmol/l 
(Table 1). Participants 1 and 10 did not provide their blood 
sample in month 0, but their serum fluoride values in 
month 1 were <0.2 and 1.3 μmol/l, respectively. This out-
come suggests that all participants were within the identi-
fied healthy range when methoxyflurane was introduced 
into clinical practice.
The results in Table 1 show a mild variation of serum fluo-
ride for the participants over the 24-month study period. 
One test result exceeded the 95% CI for healthy serum 
fluoride (participant 6 in month 4, Sf = 4.0 μmol/l), while 
3 other test results were at the upper limit of the 95% CI 
(participants 7 and 9 in month 4; and participant 10 in 
month 18, Sf = 2.2 μmol/l on each occasion). This set of 
higher results suggests the possibility of an effect from 
occupational exposure to methoxyflurane, and the pos-
sibility of methoxyflurane inconsistently causing an el-
evation of serum fluoride above a normal healthy adult 
range.
Comparison with the renal toxic threshold
Serum fluoride remained well below the previously sug-
gested single-dose renal toxic threshold of 40 μmol/l [5,6]. 
The peak serum fluoride value determined by this research 
(Table 1) is only 10% of that threshold. There is no data 
available of whether this toxic threshold would change 
with frequent exposure and chronic serum fluoride eleva-
tion. However, this difference and the results presented 
imply safety from renal toxicity for these ambulance of-
ficers occupationally exposed to methoxyflurane.
Skeletal fluorosis risk
Skeletal fluorosis is associated with a wide range of 
serum fluoride levels [21,22,29,30,32,33], from 45 patients 
pant’s serum fluoride results against a constant serum flu-
oride value equal to that participant’s initial test result, to 
identify whether a statistically significant change occurred. 
No results met the criteria for statistical significance, 
though several were close.
Identification of skeletal fluorosis thresholds
Overall, 6 studies reporting serum fluoride levels asso-
ciated with skeletal fluorosis were identified [21, 22, 29, 
30, 32, 33]. The lowest reported serum fluoride level for 
a person with some evidence of skeletal fluorosis was 
3.42 μmol/l [29]. However, the lowest serum fluoride level 
for a person satisfying skeletal fluorosis criteria with spinal 
bone mineral density measured by dual-energy X-ray ab-
sorptiometry greater than 2 standard deviations above 
the control mean was 3.65 μmol/l [29]. This latter value 
was selected as the lowest observed adverse effect level 
(LOAEL). The lowest serum fluoride at which standard 
radiologic features of skeletal fluorosis were evident was 
16.63 μmol/l [21].
DISCUSSION
This study observed a small statistically insignificant in-
crease in serum fluoride in EMTs after methoxyflurane 
had been introduced into clinical practice (Tables 1 and 2, 
Figures 2 and 3). A power analysis was conducted to iden-
tify the appropriate sample size to detect large differenc-
es (1 μmol/l) in serum fluoride, accounting for attrition. 
The study recruited the number of participants identified 
by that power analysis, implying that the study was appro-
priately powered to test a hypothesis of large increases in 
serum fluoride concentrations after introduction of me-
thoxyflurane. However, the large number of missing test 
results limits the determination of statistical significance.
Comparison with a healthy serum fluoride range
The meta-analysis determined a 95% CI for healthy serum 
fluoride to be 0.21–2.11 μmol/l (Figure 1). This meta-anal-
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Serum fluoride accumulation
The Wilcoxon signed-rank test evaluates a hypothesis of 
similarity between repeated groups of measurements of 
the same subjects. These tests did not identify any statisti-
cally significant differences in blood test results compared 
with results from month 0. The Kolmogorov-Smirnov test 
evaluated a hypothesis of similarity for each participant’s 
test results over the study period from their baseline. 
These tests also did not identify statistically significant 
changes in serum fluoride for any participant (Tables 1 
and 2). Therefore, this study provided no statistically sig-
nificant evidence that occupational exposure to methoxy-
flurane led to increasing serum fluoride. More frequent 
serum fluoride sampling may have improved the likeli-
hood of achieving statistical significance.
Limitations
This research has a number of limitations. To protect par-
ticipants’ anonymity, ethical approval was not sought for 
the collection of demographic data such as participants’ 
age, sex, or fluoride intake from fluoridated water or other 
sources, as the group of ambulance officers being ap-
proached is relatively small and such information would 
potentially identify them to the study authors. Therefore, 
the effect of these variables cannot be determined. Me-
thoxyflurane was introduced into practice on the June 1, 
2017. Due to ethical and organizational constraints, 
month 0 blood tests were taken on June 15–July 4, 2017. 
with mean serum fluoride of 5.79 μmol/l associated with 
a meas ura ble change in bone mineral density [29] to a case 
report with serum fluoride of 205.28 μmol/l associated 
with pronounced painful skeletal changes [22]. This very 
wide range of serum fluoride values, with the highest value 
identified in this study corresponding to approx. 2–69% of 
those mean values, coupled with an absence of case studies 
of skeletal fluorosis in ambulance officers at other sites ad-
ministering methoxyflurane repeatedly, implies a reason-
able but unsatisfying degree of safety.
The LOAEL for skeletal fluorosis is 3.65 μmol/l of 
serum fluoride, likely due to long-term ingestion of con-
taminated ground water [29]. One result exceeded this 
LOAEL (participant 6 in month 4, Sf = 4.0 μmol/l), sug-
gesting a possibility of skeletal fluorosis effects for some 
ambulance officers (1 in 10 EMTs in this case). This sub-
ject was informed by the study author of that result com-
pared with the identified thresholds, and encouraged to 
contact a general practitioner. That participant’s serum 
fluoride level did not remain above the LOAEL in sub-
sequent tests, and the period of elevated serum fluoride 
required for the adverse effect to occur is unknown. 
Notably, the highest serum fluoride result was 24% of 
the lowest level known to be associated with radiologic 
evidence of fluorosis [21]. Figure 4 illustrates serum 
fluoride results for all participants compared with iden-
tified clinical thresholds for skeletal fluorosis and renal 
toxicity.















Figure 4. Summary of all participants’ serum fluoride results compared with clinical thresholds, June 2017–June 2019, New Zealand
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rane. Further quantification of skeletal fluorosis risk may 
be a valuable subject for future research.
The present study involved the presence of an activated 
carbon filter on the patient’s exhalation. Filtration is a po-
tentially important factor that should be considered in 
the interpretation and design of studies. Given other evi-
dence for risks associated with occupational exposure to 
methoxyflurane, it is suggested that conservative clinical 
practice would be to use activated carbon filters until such 
time as the effect of filtration can be better understood.
Investigation of the degree of occupational exposure experi-
enced under various conditions would assist in the determi-
nation of risks faced by ambulance officers and healthcare 
workers in other settings. Serum fluoride measurement with 
greater fidelity (more frequently than approximately every 
1–6 months as was the case in this study), and/or a larger 
number of subjects than included in this study, might im-
prove the degree of certainty of the risk posed by occupation-
al methoxyflurane exposure. Determination of serum fluo-
ride from methoxyflurane exposure in environments other 
than ambulance care, such as in a hospital or clinical setting, 
would be of value to the wider healthcare community.
Until the degree of the risk posed by methoxyflurane is 
further clarified, it may be beneficial for ambulance offi-
cers and other healthcare staff to maximize environmental 
ventilation in order to minimize their occupational expo-
sure and consequent skeletal fluorosis risk.
CONCLUSIONS
There was no statistically significant change in the serum flu-
oride results across the combined data set. Thus, there was 
no evidence of EMTs’ exposure to methoxyflurane resulting 
in sustained increased serum fluoride levels. There was no 
evidence to support the hypothesis that increasing serum 
fluoride occurs over a prolonged (up to 2-year) period. One 
serum fluoride result exceeded, and some serum fluoride re-
sults reached, the upper limit of the expected reference range. 
The maximum serum fluoride level was only 10% of the pro-
Therefore, the participants may have been exposed to 
methoxyflurane prior to the baseline blood test, and that 
result might not represent a non-exposed value, thus lim-
iting the potential to detect any increase from a non-ex-
posed baseline. This study, nonetheless, determined that 
the levels of serum fluoride in a cohort of EMTs were gen-
erally within normal limits.
Furthermore, the study was not blinded and the par-
ticipants were able to opt-in to receiving each test result. 
Therefore, the participants may have adjusted their me-
thoxyflurane administration behavior in response to their 
test results. This potential self-regulation of administra-
tion amongst the participants may have led to lower than 
representative rates of administration and, thus, exposure. 
However, any change in behavior cannot be confirmed 
within the constraints of the ethical approval obtained, 
and this study makes no attempt to correlate frequency or 
duration of exposure of individual participants with serum 
fluoride results.
Clinical implications
Previous studies have attempted to determine occupation-
al risk by extrapolation from limited patient anesthesia 
data [6,7,11]. This research is the first report of serum fluo-
ride associated with occupational exposure in the modern 
setting using the Penthrox® inhaler. Direct measurements 
of serum fluoride provide a much greater certainty than 
extrapolation over several orders of magnitude. While ex-
trapolation did not identify values approaching a single-
dose renal toxic threshold, or within a skeletal fluorosis 
range, the direct measurement undertaken in this research 
provides more convincing evidence of safety. Additionally, 
this study provides evidence of renal safety and evidence 
suggesting that fluoride accumulation does not occur in 
EMTs with repeated methoxyflurane exposures, which 
extrapolation from single high-dose data cannot provide. 
Furthermore, skeletal fluorosis is identified as a risk asso-
ciated with EMTs’ occupational exposure to methoxyflu-
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